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Background: Pediatric randomized controlled trials (RCTs) are susceptible to a high risk of bias. We examined the
barriers and facilitators that pediatric trialists face in the design and conduct of unbiased trials.
Methods: We used a mixed methods design, with semi-structured interviews building upon the results of a
quantitative survey. We surveyed Canadian (n=253) and international (n=600) pediatric trialists regarding their
knowledge and awareness of bias and their perceived barriers and facilitators in conducting clinical trials. We then
interviewed 13 participants from different subspecialties and geographic locations to gain a more detailed
description of how their experiences and attitudes towards research interacted with trial design and conduct.
Results: The survey response rate was 23.0% (186/807). 68.1% of respondents agreed that bias is a problem in
pediatric RCTs and 72.0% felt that there is sufficient evidence to support changing some aspects of how trials are
conducted. Knowledge related to bias was variable, with inconsistent awareness of study design features that may
introduce bias into a study. Interview participants highlighted a lack of formal training in research methods, a
negative research culture, and the pragmatics of trial conduct as barriers. Facilitators included contact with
knowledgeable and supportive colleagues and infrastructure for research.
Conclusions: A lack of awareness of bias and negative attitudes towards research present significant barriers in
terms of conducting methodologically rigorous pediatric RCTs. Knowledge translation efforts must focus on these
issues to ensure the relevance and validity of trial results.
Keywords: Clinical trials as topic, Risk of bias, Pediatrics, Mixed methodsBackground
“We as an institution, as a profession, don’t actually sell
research as being an important thing that we do in hos-
pitals. And it should be.”
There is a growing body of literature documenting the
methodological limitations of published randomized
controlled trials (RCTs) in pediatrics [1-7]. Of particular
concern is the evidence that RCTs in child health are* Correspondence: michele.hamm@ualberta.ca
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reproduction in any medium, provided the orsusceptible to a high risk of bias, increasing the likeli-
hood that reported treatment benefits and/or harms are
being exaggerated [8-10]. In order to ensure clinical rele-
vance and to prevent unnecessary and wasteful research,
it is crucial that measures are taken to maximize the in-
ternal validity of studies that are conducted [11,12]. The
global investment in research is enormous, with funding
of $100 billion annually [11], plus the time and effort
committed by the researchers, clinicians, and children
and families. When participants agree to take part in a
trial, they expect that the study will be conducted and
reported to the highest standard to accurately answer
the research question. When this expectation is met,
trial results are important in providing children with theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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is conducted instead, research dollars and professionals’
time are wasted, and the children’s contributions are
unavailing.
Evidence describing the negative impact of bias on
RCTs and how to minimize it is available [13-22], as is
research on a number of specific challenges inherent in
conducting RCTs in pediatrics [23-27], such as recruit-
ment and consent procedures. However, the research-
practice gap regarding methodological rigor in this
population has not yet been addressed.
As the first step in the development of a knowledge
translation strategy to address the reduction of bias in
pediatric RCTs, the objective of this study was to deter-
mine and describe the barriers and facilitators that
pediatric trialists face in the design and conduct of un-
biased trials, with an emphasis on the Canadian context.
Quantitative survey and qualitative interview data were




We used an explanatory mixed methods design, with
semi-structured interviews building upon the results of a
quantitative survey. We connected data from the two
phases to provide detailed descriptions of the barriers
and facilitators pediatric trialists face in designing and
conducting studies with high internal validity [28]. We
obtained ethical approval from the Health Research Eth-
ics Board at the University of Alberta.
Data collection
Quantitative: survey
We sent an Internet-based survey (SurveyMonkey) to a
sample of Canadian and international pediatric trialists
between September 2010 and February 2011. We
searched the Cochrane Central Register of Controlled
Trials for pediatric RCTs published in 2008 and 2009
and identified 7,535 articles. Corresponding authors of
all relevant trials identified using a Canadian-specific
search filter (n=90), and a geographically representative
sample of 600 international trialists chosen from a ran-
domly ordered list were invited to participate in the sur-
vey. We sent an invitation e-mail with a link to the
survey and two reminder e-mails separated by two week
intervals. The questionnaire was informed by the
Cochrane Collaboration’s Risk of Bias tool [29], the
BARRIERS Scale [30], and the framework proposed by
Cabana et al. [31], described in Table 1.
Twelve methodologists and clinicians evaluated the
questionnaire for appropriateness and accuracy of con-
tent and 5 national and international pediatric trialists
completed pilot testing for clarity and ease of use; wemade revisions based on their feedback. The survey
included 23 questions and pilot testing indicated that it
would take approximately 15 minutes to complete. We
developed items to determine: 1) researcher knowledge
and awareness of bias; and 2) perceived barriers and
facilitators in conducting clinical trials.
Due to a low response rate using the sample described
above (154/644; 23.9%), we expanded the survey popula-
tion to recruit participants from the membership of the
Maternal Infant Child and Youth Research Network
(MICYRN), a Canadian network linking investigators
from 17 academic health centres involved in pediatric
clinical research. We identified potential respondents
through a publicly available network inventory main-
tained by MICYRN (http://www.micyrn.ca/Networks.
html) and invited all individuals listed as network con-
tacts via email to participate in both the survey and the
interview portion of the study (n=163). The survey
included an item asking whether respondents would be
willing to be contacted for an interview, and if so, to
provide their name and preferred means of initial con-
tact. As a result of problems with access to SurveyMon-
key, we administered this wave via REDCap, an alternate
secure, online application for managing surveys.
Qualitative: interviews
Due to low participation rates from survey respondents,
we augmented recruitment with members of MICYRN
with trial experience and referrals from participants and
established pediatric trialists. We used purposive sam-
pling based upon pediatric subspecialty and geographic
location, aiming to reach saturation, which typically
occurs around 12 participants [33]. Interviews followed
a semi-structured format built upon the results of the
survey and were focused on participants’ experiences
and attitudes towards conducting pediatric research and
how these interacted with the appropriate design and
conduct of methodologically sound trials. Each partici-
pant was sent an electronic consent form that they
signed and returned via fax or email prior to the con-
duct of the interview. Interviews were 30 to 60 minutes
and conducted by telephone by the lead author between
April and July 2011. All interviews were recorded and
transcribed verbatim.
Data analysis
We analyzed survey data descriptively, using means and
standard deviations, medians and interquartile ranges
(IQR), or proportions where appropriate. We used content
analysis to code interviews, identifying categories in the
data and patterns in beliefs and values that could help ex-
plain the potential for bias in pediatric RCTs [34]. Coding
was conducted by the lead author in consultation with the
rest of the study team. We conducted qualitative data
Table 1 Tools used for survey development
Tool Description
Risk of Bias tool Used to assess the internal validity of RCTs. It is comprised of seven domains supported by empirical evidence: sequence
generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessors, incomplete outcome
data, selective outcome reporting, and “other” sources of bias [29].
BARRIERS Scale Widely used to identify general barriers to research utilization, particularly in nursing. Barriers are categorized into factors related to
the individual, setting, research, and presentation [30,32].
Cabana
framework
Developed by Cabana et al. [31] as part of an evaluation of barriers to physicians’ adoption of clinical practice guidelines. This
framework includes 10 major factors, grouped into categories related to knowledge, attitudes, and behaviour.
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process. We integrated the survey and interview data at
the data interpretation phase [35], using the method of
connecting data [28]. We used Stata and NVivo to manage
quantitative and qualitative data, respectively.
Results
The survey response rate was 23.0% (186/807) and 13
interviews were conducted. Characteristics of the survey
and interview participants are described in Tables 2 and
3 and Additional file 1. Survey results were similar
across geographic boundaries and were therefore com-
bined and used as a whole to inform a detailed examin-
ation of how barriers and facilitators manifest in
Canadian research. Results are presented according to
their classification as individual, institutional, or policy
level factors. Themes are outlined in Table 4.
Individual factors
Survey findings indicated that 68.1% of respondents
agree that bias is a problem in pediatric RCTs and 72.0%
reported that they felt there was sufficient evidence to
support the need to change some aspects of how RCTs
are conducted. However, knowledge of bias among
respondents was variable. There was no consistency in
responses to questions which asked the respondent to
rate the degree to which they agreed that a study design
factor would introduce bias into a study. Identification
of specific biases was strongest for sequence generation,
blinding, and selective outcome reporting, while there
was more uncertainty surrounding identification of pro-
blems with allocation concealment, incomplete outcome
data, and “other sources of bias” (see Additional file 2).
Despite this range of awareness of issues relevant to bias,
94.2% of respondents felt confident in their ability to
evaluate the quality of published trials.
The interviews highlighted two important themes
regarding barriers and facilitators at the individual level:
knowledge and training regarding research methods, and
engagement or ownership in the research process
(Table 5). While most survey respondents indicated that
bias is a problem, the interview data suggested that trial-
ists often do not have the knowledge to first, recognize,
and second, address bias in their studies. They oftenmentioned a lack of formal training, instead relying on
skills learned on the job.
Conversely, a sense of ownership can contribute to a
rigorous study design. Actively taking responsibility for
the direction of the trial was seen as an opportunity for
the investigators to generate enthusiasm, gain support,
and educate colleagues about the rationale for rigorous
methodology and how it impacts the ability to accurately
answer the research question.
“Listen to what [your colleagues] need to execute the
study so that when you develop your protocol, you’ve
built that into the approach. Or, if you couldn’t,
you’ve at least had that dialogue with them about how
scientifically you can’t be as flexible as might be
ideal. . . so that they at least understand the rationale.”
Institutional factors
While 93.0% of survey respondents demonstrated an
interest in learning about and staying current with lit-
erature describing and analyzing research methods, only
50.3% felt that they were able to do so due to other
constraints. Logistical issues such as meeting institu-
tional requirements (29.2%) and having sufficient staff
(30.4%) were identified as challenges, while access to
knowledgeable colleagues (92.8%) was identified as the
most significant facilitator (see Additional file 2).
Consistently, interview respondents felt that environ-
mental factors within their institutions were not condu-
cive to research, often as the result of perceptions of
research (Table 6). They reported the underlying culture
to be overwhelmingly negative towards research at all
levels, with resistance from trainees, nurses, physicians,
administrators, and the pharmaceutical industry. While
respondents felt that the products of research tend to be
valued once they are demonstrated to improve practice,
they stated that there is little appreciation of the meth-
ods necessary to achieve that goal. Logistically, respon-
dents felt that having staff dedicated to research would
improve this situation, as research procedures would
then not consistently be placed at the lowest priority.
Recognition of the division between the paradigms of
clinical care (e.g., protecting the interests and comfort of
patients) and clinical research (e.g., maintaining clinical
Table 2 Demographics of survey population
Variable n (%)
Total returned surveys 186/807 (23.0)
Undeliverable surveys 46/853 (5.4)





No response 38 (20.4)
Involvement in RCTs – median number of trials (IQR)
As a principal investigator 3 (1–5)





Allied healthcare 13 (7.0)
Nursing 11 (5.9)
Other 9 (4.8)
No response 38 (20.4)
Pediatric subspecialty
Public health 16 (8.6)
Developmental, psychosocial, and learning problems 14 (7.5)
Mental health or psychiatry 13 (7.0)
Neonatology 11 (5.9)
Endocrinology and nutrition 10 (5.4)
Emergency medicine or critical care 9 (4.8)
Infectious diseases 9 (4.8)
Hematology or oncology 7 (3.8)
Oral health 6 (3.2)
Allergy and immunology 5 (2.7)
Anesthesia 5 (2.7)
General pediatrics or family medicine 5 (2.7)
Other 47 (25.2)
No response 29 (15.6)
Geographic region of corresponding author
Asia 10 (5.4)
Australia and New Zealand 12 (6.5)
Canada 47 (25.2)
Europe 25 (13.4)
South America 3 (1.6)
USA 46 (24.7)
No response 43 (23.1)
Setting of employment*
University or academic centre 124 (66.7)
Table 2 Demographics of survey population (Continued)
Hospital 48 (25.8)
Solo practice 4 (2.2)
Group practice 4 (2.2)
Industry 4 (2.2)
Other 7 (3.8)
No response 39 (21.0)
*More than one selection possible.
Further details on collapsed categories are available from the authors.
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investigators often have difficulty with this distinction,
which allows for the possibility of compromised trial
protocols.
“I think a lot of investigators really have a hard time
separating what decision they would make clinically
from what decision they would make as part of a
trial. . . because the feeling is I want to be convenientTable 3 Characteristics of interview participants
Variable n (%)








Medicine and Research 4 (30.8)
Pediatric subspecialty
Anesthesiology 1 (7.7)
Clinical epidemiology 1 (7.7)
Critical care 2 (15.4)
Emergency medicine 3 (23.1)






Geographic region of participant
Alberta 2 (15.4)




Table 4 Interview themes and relevance to risk of bias
Category Theme Relevance to risk of bias
Barriers
Individual Knowledge - Little formal training in research methods, therefore bias is likely due to a lack of knowledge of how it is
introduced.
Institutional Clinical care vs. clinical
research
- Decisions made clinically rather than per the trial design can lead to protocol deviations, e.g. interference
with randomization sequence.
Culture - Research is often viewed negatively in the clinical setting, leading to little value placed on following the trial
protocol when it deviates from usual care.
Logistics - Demands on time and space can put research at a low priority and tasks may not be done according to
protocol, e.g. ensuring safeguards are in place to maintain blinding.
Policy Administration - Budget constraints can limit hiring external methodological expertise if necessary; ethics requirements for
methodology are inconsistent, leaving protocols subject to change.
Pediatric-specific
challenges
- Blinding parents; investigators are less willing to inconvenience families with strict protocols; fewer trials has
meant less competition for developing the best methodology.
Facilitators
Individual Ownership - The trial will be more successful when the investigators take responsibility for generating support and
ensuring rigor.
Institutional Acceptance - Researcher understanding of the clinical setting facilitates the acceptance of research methods by the
practitioners.
Cohesive study team - Consulting experienced trialists and methodologists contributes to a more rigorous and well thought out
study, in terms of both validity and feasibility.
Infrastructure - Protected research time and dedicated research staff facilitate trial design and conduct.










Table 6 Perspectives on institution-level factors
Barriers
09 I think that other people view [research] as kind of a thorn in their
side. It’s something they play along with if they have to and the
division head tells them they have to.
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an expert in this clinical area, and I don’t think they
realize that there’s a pretty clear demarcation between
what you do in clinical care and what you do as
research.”ble 5 Perspectives on individual-level factors
rriers
Probably we don’t look at, we don’t know all the bias that can be,
that can happen in a trial because we don’t check, we don’t believe
there’s bias. We may miss some, we may forget some, and then do
not report the bias because we don’t know it exists.
I’ve kind of learned on the job, which is why I’m not fully confident
that I have all the skills.
Because there’s almost zero research training in the clinical
curriculum for most clinicians these days. Like there’s almost
nothing in the med school program, there’s almost nothing in the
rehab program – there really needs to be somebody on the
protocol who’s got a little bit more training.
Well you know it’s often when people go to write up a protocol,
either they’re not totally aware of how this whole bias thing works
and to them, you know the fact that you randomize people by the
day of the week they present, that sounds good enough.
cilitators
So you really have to take the time to engage people and be the
one that’s proactive, engaging them. Because they’re busy, they
might not even know what your study is unless you’re the change
agent that really goes out there and talks to them about it and gets
them motivated about why you think it’s important.
09 You work separately or in parallel and not necessarily the team as
much, and I think that’s part of the challenge. You view the study
as important, they view the results as important, but they don’t
want to go through the pain of finding out the results because it
impacts on what they do clinically.
03 Where we get into the biggest problems is if we take a person
who’s very knowledgeable and very confident in how to care for
patients with [disease], so they’re experts and masters in clinical
care, and they just assume that that carries over into being an
expert in clinical research.
Facilitators
01 So because we get donated funds, a fairly large amount of donated
funds proportionally speaking in [disease], we’re able to support the
personnel to perform the trials.
06 We have the help of the research institute and you can have a
person for any kind of question or any kind of design that can help,
and we have access to those kinds of resources.
09 I think the fact that [research network] is there enables you to think
of multi-centre RCTs, whereas if it wasn’t there, you’d kind of have
to go and find things from scratch. But by existing, it brings people
together with shared interests and I think that that is a huge asset
when it comes to even the thought of designing a multi-centre
RCT. It’s like you want to design one for [research network].
07 [Research institute] has a great model where they require any grant
that’s going out for external funding to be reviewed by three
people from inside the institution.
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ceived as a threat to research varied according to the size
of the site of the respondent. A clear distinction was
noted between larger research-intensive institutions and
other sites in which researchers struggled due to a lack
of infrastructure. Trialists from the former viewed the
conduct of research much more positively and generally
felt that they had the necessary resources available to
conduct rigorous trials, while those from the latter
reported greater levels of difficulty positioning their re-
search as an important part of the clinical landscape.
“Space, resources, and training for research assistants,
research managers, graduate students. . . there’s all
sorts of hurdles and headaches around those things
that I think most established clinical research
programs. . . already know how to make the system
work.”
Similar to the survey results, cohesive study teams with
positive working relationships were reported as the most
significant facilitator to conducting rigorous trials. At the
institutional level, this often included combining the ex-
pertise of experienced trialists, methodologists, and the
staff that would be responsible for implementing the trial;
however, this integration was more common at sites with
more support for research. Positive relationships were also
mentioned in the context of subspecialties, with product-
ive research networks across sites enabling researchers to
benefit from a collective expertise, as well as facilitating
study-specific elements such as the conduct of multi-
centre trials. A final facilitator, which was more prominent
in certain institutions than others, was a reliable internal
review process. Respondents viewed this as a major asset
when it was available, but many felt that existing processes
were fragmented and inconsistent.
Policy factors
All interview respondents felt a lack of incentive to con-
duct pediatric trials. Difficulty in securing funding wasTable 7 Perspectives on policy-level factors
Barriers
13 We all tend to want to make the budget as small as we can to
increase our chances to actually get it funded and the reality is that
some trials really require the full-time effort of somebody who’s got
a lot of experience, and therefore comes with a price tag. And it
can be hard to make the argument to ensure that you’ve got
funding, right? So I think that’s where you start cutting other
corners, and you don’t have the data quality, and at the end of the
day, you maybe don’t have the rigorous, homerun kind of trial that
you had envisioned.
02 (regarding ethics review at multiple sites) Most of the problem is to
ask for revisions and they are not consistent one between the
others. So you can have a question in one and the other one. . .
wants a different answer.frequently mentioned, but beyond that, participants
reported that it is challenging to justify including finan-
cial support for a methodologist in grant application
budgets in an environment where the funds awarded are
anticipated to be less than requested. In this context,
there is less assurance that study teams can include the
necessary expertise. Meeting the requirements of several
research ethics boards also presents a challenge, particu-
larly with the preponderance of multi-centre trials in
pediatrics. With separate ethics approval processes at
each institution, the process can be lengthy and proto-
cols are oftentimes changed to meet the inconsistent
requests of the individual review panels (Table 7).
Specific biases and pediatric-specific challenges
Addressing specific biases, survey and interview respon-
dents reported challenges with blinding most frequently,
which included the cost of providing a placebo, difficul-
ties in blinding non-pharmacological interventions, and
blinding all relevant parties, including parents. Other
issues that were mentioned included difficulty getting
adequate follow up in settings without an established
clinician-patient relationship, parental resistance to
randomization, and group imbalances due to small sam-
ple size.
Discussion
Bias is a recognized concern among pediatric trialists;
however they may be lacking the knowledge, willingness,
or resources to properly address it. Internal validity did
not emerge as a primary concern in the analyses, being
overshadowed by issues related to the pragmatics of run-
ning a trial and the generalizability of the results. While
these issues warrant a great deal of consideration, it is
crucial that studies start out being methodologically
rigorous as this is a prerequisite for generalizability.
The major barriers to minimizing risk of bias in trials
were related to awareness and environment. With little
emphasis on research methodology in clinical curricula,
many investigators are not adequately prepared to design
trials with high levels of internal validity or to recognize
and attend to issues as they arise. The existing ad hoc
training system very likely contributes to an emphasis
on certain areas and a deficit in others, as demonstrated
by the disproportionate focus by respondents on issues
related to external validity (i.e., generalizability of study
results), despite being questioned on issues relevant to
internal validity (i.e., avoiding bias through methodo-
logically rigorous design). Additionally, the predomin-
antly negative attitudes surrounding the research process
reinforce the acceptance of sub-optimal RCTs. While re-
search findings may be valued, more effort is required to
ensure that the importance of high quality research is
recognized at all stages, and by all stakeholders. Pediatric
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vironment that fosters research. Available infrastructure
and consistency in study protocols has resulted in the
successful integration of research and clinical care lead-
ing to marked improvements in survival and other out-
comes [24,36,37]. By embracing research as a critical
component of providing best care, rather than viewing it
as an imposition, investigators and clinicians in oncology
have shown that setting a standard for conducting rigor-
ous trials is an achievable goal with tangible benefits and
impressive health outcomes.
Positive relationships that support the development of
an interest in research are particularly relevant in an en-
vironment in which most training is dependent on men-
torship and reinforcement from experienced trialists.
Within this context, clinician-scientists have a key role
in bridging the gap between the worlds of research and
clinical practice. Combining knowledge of proper meth-
odology with an appreciation for the demands of the
clinical setting will increase the likelihood of producing
both valid and realistic trials. Research networks such as
the Canadian Critical Care Trials Group (CCCTG) and
Pediatric Emergency Research Canada (PERC) have been
quite successful in using this strategy, facilitating high
quality trials by promoting a positive culture of research,
providing access to individuals with expertise, and offer-
ing support and collegiality [38,39].
With a solid evidence base demonstrating the gaps in
methodological quality in pediatric RCTs [1-10], the re-
search agenda must now focus on knowledge translation.
Using barriers and facilitators identified by the target end-
users, it will be important to develop tailored strategies to
overcome the gap between what is known about methodo-
logical processes and how trials are designed and con-
ducted in practice. This is one of the stated aims of StaR
Child Health, an international initiative dedicated to im-
proving the quality of pediatric clinical research [40].
Strengths and limitations
An advantage of this study is that it combines the breadth
of survey responses with the depth of interview responses,
allowing for a detailed picture of the barriers and facilitators
pediatric trialists face in the conduct of methodologically
rigorous trials. While the response rate to the survey was
low, bringing into question the representativeness of the
sample, it was in line with evidence that both electronic
surveys [41] and physician surveys [42] are associated with
low responses. However, respondents represented a wide
range of pediatric specialties, training backgrounds, and
geographies, helping to give shape to the subsequent inter-
views. While they may have represented researchers with a
higher level of interest in methodology, the survey
responses were used to form the interviews, in which
researchers with trial experience were of interest so as to beable to account for the barriers and facilitators in pediatric
research with first-hand knowledge. The recruitment of
additional survey participants from the membership of
MICYRN slightly changed the balance of geographical rep-
resentation; however the Canadian context was weighted
heavily throughout the study, therefore our emphasis was
unchanged. The response rate to requests for interview par-
ticipation was also low, but with our expanded recruitment
strategy we were able to achieve saturation. The interviews
emphasized the Canadian context and therefore can be
used to inform future developments within the national
health care and research framework, as well as provide con-
siderations relevant to other settings.
Conclusions
Clinical research is inherently challenging, but these results
can be used to focus efforts on improving the validity of
trials that are conducted. The evidence is clear that im-
provement is necessary in pediatric RCTs and a substantial
body of knowledge has accumulated around how to
minimize bias. Before trials can improve, though, awareness
of bias and attitudes towards research must be addressed.
Research must be reframed as a valuable component of
health care education, practice, and decision-making.
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